Omega-3 (n-3) Fatty Acid-Statin Interaction: Evidence for a Novel Therapeutic Strategy for Atherosclerotic...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Atherosclerotic cardiovascular disease (ASCVD) management involves lifestyle changes and medications like statins and omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)).
• Statins primarily lower low-density lipoprotein cholesterol (LDL-C), while omega-3 fatty acids target triglyceride (TG) levels.
• Both drug classes possess overlapping pleiotropic effects, including anti-inflammatory actions and plaque stabilization, addressing residual cardiovascular risk.

Purpose of the Study:

• To explore potential interactions between omega-3 fatty acids and statins in ASCVD prevention and treatment.
• To highlight novel insights into how these interactions may combat persistent inflammation.
• To discuss the role of specialized pro-resolving mediators (SPMs) in this context.

Main Methods:

• Review of existing literature on statin-omega-3 fatty acid interactions.
• Analysis of evidence regarding the role of SPMs in inflammation resolution.
• Discussion of the implications for clinical practice in ASCVD management.

Main Results:

• Statins and omega-3 fatty acids share anti-inflammatory properties and can stabilize atherosclerotic plaques.
• EPA and DHA are precursors to SPMs, which actively resolve inflammation.
• Emerging evidence suggests statins may enhance the production of certain SPMs, indicating a synergistic interaction.

Conclusions:

• The interaction between statins and omega-3 fatty acids, particularly through SPM pathways, presents a promising strategy for managing residual inflammatory risk in ASCVD.
• SPMs represent a novel therapeutic target with potential benefits beyond omega-3 fatty acids alone.
• Further research into these interactions could refine ASCVD treatment protocols.